Synergistic Anemia Treatment Systems

Integrating HIF prolyl hydroxylase inhibitors with AI, IoT, blockchain, and nanomaterial technologies to create more effective and personalized anemia treatment systems.

The original patent disclosed compositions and methods for treating anemia using HIF prolyl hydroxylase inhibitors. However, the existing treatment methods have limitations in terms of dosing accuracy, patient data management, and treatment efficacy monitoring. The new inventive concept addresses these limitations by combining HIF prolyl hydroxylase inhibitors with distinct technologies to create a more powerful and personalized anemia treatment system.

The new inventive concept comprises four main components: (1) a HIF prolyl hydroxylase inhibitor, (2) an AI-powered dosing algorithm, (3) an IoT-enabled wearable device, and (4) a blockchain-based patient data management platform. The AI-powered dosing algorithm adjusts the dosage of the HIF prolyl hydroxylase inhibitor based on real-time patient data stored on the blockchain-based platform. The IoT-enabled wearable device monitors patient vital signs and transmits the data to a cloud-based server for analysis and personalized treatment recommendations. Additionally, the system can integrate a nanomaterial-based delivery system to enhance the bioavailability of the HIF prolyl hydroxylase inhibitor and a biomarker for monitoring treatment efficacy.

The new claims introduce the concept of integrating HIF prolyl hydroxylase inhibitors with AI, IoT, blockchain, and nanomaterial technologies, which is not disclosed in the original patent. The inventive step lies in the synergistic combination of these distinct technologies to create a more effective and personalized anemia treatment system.

Alternative embodiments of the inventive concept could include integrating the HIF prolyl hydroxylase inhibitor with other AI-powered algorithms, such as machine learning algorithms for predicting treatment outcomes or genomic analysis platforms for personalized treatment planning. Other variations could include using different types of IoT-enabled devices or blockchain-based platforms.

The synergistic anemia treatment systems have significant commercial potential in the pharmaceutical and healthcare industries, particularly in the areas of personalized medicine and precision healthcare. The target market includes patients with chronic kidney disease, chemotherapy-induced anemia, and AIDS-related anemia, as well as healthcare providers and pharmaceutical companies.